Nautilus Biotechnology (NAUT) Non-Current Deffered Revenue (2020 - 2021)
Nautilus Biotechnology (NAUT) posted Non-Current Deffered Revenue of $5.2 million for Q1 2021, little changed sequentially from $5.2 million in Q4 2020.
Nautilus Biotechnology (NAUT) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Nautilus Biotechnology has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $5.2 million in Q1 2021.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $5.2 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $5.2 million (changed N/A YoY) and the FY2020 annual result came in at $5.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was little changed at $5.2 million in Q1 2021 per NAUT's latest filing, from $5.2 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $5.2 million in Q3 2020 and troughed at $5.2 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 5.23 Mn |
| Dec 31, 2020 | 5.23 Mn |
| Sep 30, 2020 | 5.23 Mn |